Premonitory Symptoms in Migraine

XXV World Congress of Neurology
0560 Teaching Course Headache I

4th October 2021

Professor Peter J. Goadsby
Disclosure in ICJME + ACCME format
2018-2021

Dr Goadsby reports

- Grants and personal fees from
  - Amgen (erenumab)
  - Eli-Lilly (galcanezumab/lasmiditan)
  - Celgene
  - Allergan (onabotulinum toxin type A/ubrogepant/atogepant)
  - Autonomic Technologies Inc. (Pulsante SPG)
  - Biohaven (rimegepant, zavegepant)
  - Cleixo
  - Electrocore LLC (nVNS)
  - eNeura Inc (Aruena; sTMS)
  - Epalex
  - GlaxoSmithKline
  - Impel Neuropharma
  - Lundbeck/Alder Biopharmaceuticals (eptinezumab)
  - Novartis (erenumab)
  - Pfizer
  - Santara Therapeutics
  - Satsuma
  - Teva Pharmaceuticals (fremanezumab)

- Personal fees from
  - Aeon Biopharma
  - Allergan (onabotulinum toxin type A/ubrogepant/atogepant)
  - Autonomic Technologies Inc. (Pulsante SPG)
  - Biohaven (rimegepant, zavegepant)
  - Cleixo
  - Electrocore LLC (nVNS)
  - eNeura Inc (Aruena; sTMS)
  - Epalex
  - GlaxoSmithKline
  - Impel Neuropharma
  - Lundbeck/Alder Biopharmaceuticals (eptinezumab)
  - Novartis (erenumab)
  - Pfizer
  - Santara Therapeutics
  - Satsuma
  - Teva Pharmaceuticals (fremanezumab)

- Other
  - Consulting; Gerson Lerhman, Guidepoint
  - Trigemia Inc (stock options; no fees)
  - MedicoLegal work
  - Publishing: Up-to-Date, Massachusetts Medical Society, Oxford University Press, Wolters Kluwer

- Patents
  - Magnetic stimulation for headache pending licensed to eNeura (Aruena) without fee

- ACCME: I have no spousal/partner conflicts, nor relationships with companies that market, distribute or resell health care goods or services consumed by, or used on, patients unless otherwise explicitly stated.
Premonitory Symptoms of Migraine
Learning Objectives

- To recognize the non-headache symptoms of migraine
- To comprehend developments in understanding premonitory symptoms and triggers
- To describe the neurobiology of the premonitory phase
Premonitory Symptoms of Migraine

Key Messages

• Migraine is a complex, brain networks disorder (1, 2).
• Symptoms occurring before the pain phase of migraine have been recognised for many years (3).
• Symptoms, such as mood change or cognitive dysfunction, have been recognised in clinic populations (4, 5) and more broadly (6, 7).
• Functional neuroimaging has demonstrated activations during the premonitory phase, such as the hypothalamic region (8).
Premonitory Symptoms of Migraine

References